WEST

Help

Logout

Main Menu	Search Form	Posting Counts	Show S Numbers	Edit S Numbers		
				Y		

Search Results -

Term	Documents
UNIVERSAL.USPT.	67784
UNIVERSALS USPT	81
(6 AND UNIVERSAL).USPT.	4

	tents Full-Text Database	V
	16 and universal	
Refine Search		

Search History

BB Name	Query	Hit Count	Set Name
USPT	l6 and universal	4	<u>L7</u>
USPT	15 and (medium or media)	36	<u>Ĺ6</u>
USPT	l4 and cytolog\$4 and molecular	40	<u>L5</u>
USPT	13 and (rna or dna or protein)	1770	<u>L4</u>
USPT	11 and 12 and preservative	3318	<u>L3</u>
USPT	murexide or (chromotropic adj acid) or edta or phenanthroline or thiourea	50740	L2
USPT	formaldehyde or formalin or glutaraldehyde	82789	<u>L1</u>

WEST

Help Logout

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers

Generate Collection

Search Results - Record(s) 1 through 20 of 36 returned.

1. Document ID: US 6022951 A

Entry 1 of 36

File: USPT

Feb 8, 2000

US-PAT-NO: 6022951

DOCUMENT-IDENTIFIER: US 6022951 A

TITLE: Streptavidin mutants

DATE-ISSUED: February 8, 2000

INVENTOR - INFORMATION:

COUNTRY STATE ZIP CODE CITY NAME N/A 02114 MΑ Boston Sano; Takeshi N/A 02215 Boston MA Cantor; Charles R. 02050 N/AMA Medfield Vajda; Sandor N/AΜA 02215 Reznik; Gabriel O. Bost.on N/AMA 02215 Boston Smith: Cassandra L. 92121 N/A CA San Diego Pandori; Mark W.

US-CL-CURRENT: 530/350; 530/402, 530/808, 530/810

ABSTRACT:

The present invention relates to streptavidin proteins and peptides having a altered physical properties such as an increased stability or increased or decreased affinity for binding biotin. The invention also relates to methods for the detection, identification, separation and isolation of targets using streptavidin proteins or peptides. Streptavidin with increased or reduced affinity allows for the use of the streptavidin-biotin coupling systems for detection and isolation systems wherein it is necessary to remove of one or the other of the binding partners. Such systems are useful for the purification of functional proteins and viable cells. The invention also relates to nucleic acids which encode these streptavidin proteins and peptides and to recombinant cells such as bacteria, yeast and mammalian cells which contain these nucleic acids.

31 Claims, 27 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 28

Full Title	Oitation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image

2. Document ID: US 6020145 A

Entry 2 of 36

File: USPT

Feb 1, 2000

DOCUMENT-IDENTIFIER: US 0145 A

TITLE: Methods for determining the presence of carcinoma using the antigen binding

region of moncolonal antibody BR96

DATE-ISSUED: February 1, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hellstrom; Ingegerd	Seattle	WA	N/A	N/A
Hellstrom; Karl Erik	Seattle	AW	N/A	N/A
Bruce; Kim Folger	Seattle	WA	N/A	N/Λ
Schreiber: George J.	Seattle	WA	N/A	N/A

US-CL-CURRENT: 435/7.23; 424/1.49, 424/131.1, 424/9.6, 435/7.1, 435/7.92, 435/7.95, 530/387.2, 530/388.1

ABSTRACT:

The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sfv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

4 Claims, 76 Drawing figures Exemplary Claim Number: 1,3 Number of Drawing Sheets: 74

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWAC	Image

3. Document ID. US 6015694 A

Entry 3 of 36

File: USPT

Jan 18, 2000

US-PAT-NO: 6015694 DOCUMENT-IDENTIFIER: US 15694

TITLE: Method for stimulating an immune response utilizing recombinant alphavirus particles

DATE-ISSUED: January 18, 2000

INVENTOR-INFORMATION:

Dubensky, Jr.; Thomas W. Rancho Sant		N/A	N/A
Polo; John M. San Diego Chang; Steven M.W. San Diego Jolly; Douglas J. Leucadia	CA	N/A	N/A
	CA	N/A	N/A
	CA	N/A	N/A

US-CL-CURRENT: 435/69.3; 424/199.1, 424/204.1, 424/228.1, 424/234.1, 424/265.1, 424/274.1, 424/277.1, 536/23.5, 536/23.7, 536/23.72

ABSTRACT:

The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

11 Claims, 35 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 30

						The Land				
F	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
FUII	TIME	Citation				-				

4. Document ID: US 6015686 A

Entry 4 of 36

File: USPT

Jan 18, 2000

US-PAT-NO: 6015686

DOCUMENT-IDENTIFIER: US 6015686 A

TITLE: Eukaryotic layered vector initiation systems

DATE-ISSUED: January 18, 2000

INVENTOR-INFORMATION:

NAME Dubensky, Jr.; Thomas W. Polo; John M. Jolly; Douglas J.	CITY Rancho Sante Fe San Diego Leucadia	STATE CA CA	ZIP CODE N/A N/A N/A	COUNTRY N/A N/A N/A
Jolly; Douglas J. Driver; David A.	San Diego	CA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/410, 536/23.5, 536/23.72, 536/24.1

ABSTRACT:

The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

20 Claims, 37 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 30

End S	Title	Edation	Front	Review	Classification	Date	Reference	Claims	KOMC	Image
1 311	-									

5. Document ID: US 5985620 A

Entry 5 of 36

File: USPT

Nov 16, 1999

US-PAT-NO: 5985620 DOCUMENT-IDENTIFIER: US

TITLE: TNF-.alpha. Ribozymes

DATE-ISSUED: November 16, 1999

INVENTOR - INFORMATION:

COUNTRY ZIP CODE STATE CITYNAME NOX N/AN/AOslo Sioud; Mouldy

US-CL-CURRENT: 435/91.31; 435/243, 435/320.1, 435/325, 435/440, 435/455, 435/471, 435/6, 435/91.1, 435/91.3, 435/91.33, 514/44, 536/23.1, 536/23.2, 536/24.5

ABSTRACT:

This invention describes compounds active against TNF-.alpha. mRNA. It further describes RNA molecules capable of conferring stability to RNA in vivo through an endogenous ribozyme binding protein(s). Possible mRNA molecules to be stabilized include ribozymes, antisense molecules and mRNA encoding polypeptides useful for protein production. The ribozymes and antisense molecules described herein are useful in mammals and plants, particularly suited for viral diseases. Methods of production and methods of use are also described.

24 Claims, 47 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 30

	Title Çitation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
Full	Title Tranon	1 12/11							arts management

6. Document ID: US 5980896 A

Entry 6 of 36

File: USPT

Nov 9, 1999

US-PAT-NO: 5980896

DOCUMENT-IDENTIFIER: US 5980896 A

TITLE: Antibodies reactive with human carcinomas

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

INVENTOR-INFORMATION:	CITY	STATE	ZIP CODE	COUNTRY
NAME	~			N/A
Hellstrom; Ingegerd	Seattle	WA	N/A	•
Hellstrom; Karl Erik	Seattle	WA	N/A	N/A
	Seattle	WA	N/A	N/A
Bruce; Kim Folger	Redmond	WA	N/A	N/A
Schreiber; George J.		WA	N/A	N/A
Siegall: Clay	Edmonds		•	N/A
McAndrew; Stephen	Newtown	PA	N/A	IV/ A

US-CL-CURRENT: 424/183.1; 424/134.1, 424/135.1, 424/136.1, 424/138.1, 424/141.1, 424/155.1, 424/178.1, 424/181.1, 530/387.3, 530/387.5, 530/387.7, 530/391.7

ABSTRACT:

The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysFE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the cardinoma dells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody commonent of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations. 35 Claims, 76 Drawing figures

Full Title Citation Front Review Classification Date Reference Claims KWIC Image

7. Document ID: US 5939265 A

Entry 7 of 36

File: USPT

Aug 17, 1999

US-PAT-NO: 5939265

DOCUMENT-IDENTIFIER: US 5939265 A

TITLE: Reagents and methods useful for detecting diseases of the lung

DATE-ISSUED: August 17, 1999

INVENTOR - INFORMATION:

INAEMICK, INCOMMITTON.		am - mm	DAD CODE	COUNTRY
NAME	CITY	STATE	ZIP CODE	~
Cohen; Maurice	Highland Park	IL	N/A	N/A
Friedman; Paula N.	Deerfield	ΙL	N/A	N/A
Gordon; Julian	Lake Bluff	IL	N/A	N/A
Hodges; Steven C.	Buffalo Grove	IL	N/A	N/A
Klass; Michael R.	Libertyville	IL	N/A	N/A
Kratochvil; Jon D.	Kenosha	WI	N/A	N/A
Roberts-Rapp; Lisa	Gurnee	ΙL	N/A	N/A
Russell: John C.	Kenosha	WI	N/A	N/A
	Libertyville	IL	N/A	N/A
Stroupe; Steven D.	TILDEL CY VIIIC			

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 536/23.1, 536/23.5

ABSTRACT:

A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as LU103 and transcribed from lung tissue is described. A fully sequenced clone representing the longest continuous sequence of LU103 is also disclosed. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the lung such as lung cancer.

21 Claims, 6 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference		Image

8. Document ID: US 591970? A

Entry 8 of 36

File: USPT

Jul 6, 1999

US-PAT-NO: 5919702 DOCUMENT-IDENTIFIEE: US 19702 A

TITLE: Production of cartilage tissue using cells isolated from Wharton's jelly

DATE-ISSUED: July (, 1999

INVENTOR - INFORMATION:

COUNTRY ZIP CODE STATE CITY NAME N/A N/ALa Jolla CA Purchio; Anthony F. N/AN/AEl Cajon CA Naughton; Brian A. N/AN/A CA San Diego San Roman; Julia

US-CL-CURRENT: 435/378; 424/93.1, 435/325, 435/366, 435/377

ABSTRACT:

The invention relates to the isolation and use of pre-chondrocytes from the umbilical cord, specifically from Wharton's jelly, that give rise to chondrocytes which produce cartilage. The isolated pre-chondrocytes, or the chondrocytes to which they give rise, can be mitotically expanded in culture and used in the production of new cartilage tissue for therapeutic use. "Banks" of pre-chondrocytes or chondrocytes can be stored frozen, and thawed and used to produce new cartilage tissue as needed.
6 Claims, 15 Drawing figures

Exemplary Claim Number: 1 Number of Drawing Sheets: 11

F(1	T:46 -	Citation	Front	Review	Classification	Date	Reference	Claims	KOAC	Image
FUII	11111	Change	1 10111							

9. Document ID: US 5882864 A

Entry 9 of 36

File: USPT

Mar 16, 1999

US-PAT-NO: 5882864

DOCUMENT-IDENTIFIER: US 5882864 A

TITLE: Biomarkers and targets for diagnosis, prognosis and management of prostate disease

DATE-ISSUED: March 16, 1999

INVENTOR-INFORMATION:

COUNTRY ZIP CODE STATE CITY NAME N/A N/AOKOklahoma City An; Gang N/A N/AOK Oklahoma City O'Hara; S. Mark N/A N/A OK Ralph; David Edmond N/A N/AOK Oklahoma City Veltri; Robert

US-CL-CURRENT: 435/6; 435/91.2, 435/91.5, 435/91.51, 536/23.5, 536/24.31, 536/24.33

ABSTRACT:

Disclosed are diagnostic techniques for the detection of human prostate cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate cancer compared to normal human prostate or benign prostatic hyperplasia.

64 Claims, 16 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 15

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KOME	Image

10. Document ID: US 5879898 A

Entry 10 of 36

File: USPT

Mar 9, 1999

DOCUMENT-IDENTIFIER: US



TITLE: Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors

DATE-ISSUED: March 9, 1999

INVENTOR-INFORMATION:

NAME Tarin; David Matsumura; Yasuhiro CITY STATE ZIP CODE Oxford N/A N/A Tokyo N/A N/A

US-CL-CURRENT: 435/7.21; 435/330, 435/7.23, 435/70.21, 530/387.3, 530/387.7, 530/387.9, 530/388.2, 530/388.8, 530/388.85, 530/389.7

ABSTRACT:

There is marked over-expression of multiple spliced variants of the CD44 gene in tumor compared to counterpart normal tissue. This observation forms the basis of a method of diagnosing neoplasia by analysis of a sample of body tissue or body fluid or waste product. A new exon 6 of 129 bp has been located and sequenced. Antibodies specific to the exon have been prepared and are claimed as new compounds suitable for use in the detection of CD44 proteins and for the in vivo imaging and therapy of tumors.

13 Claims, 15 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 7

Full Title Citation Front Review Classification Date Reference Claims KWC Image

11. Document ID: US 5876923 A

Entry 11 of 36

File: USPT

Mar 2, 1999

COUNTRY

GBX

JPX

US-PAT-NO: 5876923

DCCUMENT-IDENTIFIER: US 5876923 A

TITLE: Herpes simplex virus ICP4 as an inhibitor of apoptosis

DATE-ISSUED: March 2, 1999

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY
Leopardi; Rosario Chicago IL N/A N/A
Roizman; Bernard Chicago IL N/A N/A

US-CL-CURRENT: 435/5; 424/93.1, 42±/53.2, 435/6, 435/69.2, 514/44

ABSTRACT:

The ICP4 protein of herpes simplex virus plays an important role in the transactivation of viral genes. The present invention discloses that ICP4 also has the ability to inhibit apoptosis. This function appears to reside in functional domain distinct from the transactivating function, as indicated by studies using temperature sensitive mutants of ICP4 that transactivating function at elevated temperatures. Also disclosed are methods for inhibition of apoptosis using ICP4 or an ICP4 encoding gene, such as an .alpha.4 gene, methods of inhibiting ICP4's apoptosis inhibiting function, and methods for the production of recombinant proteins and treatment of HSV infections.

8 Claims, 13 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 13

Full Title Citation Front Review Classification Date Reference Claims KMC Image

12. Document ID: US 5869045 A

Entry 12 of 36

File: USPT

Feb 9, 1999

US-PAT-NO: 5869045 DOCUMENT IDENTIFIER: US

TITLE: Antibody conjugates reactive with human carcinomas

DATE-ISSUED: February 9, 1999

INVENTOR - INFORMATION:

COUNTRY ZIP CODE STATE CITY NAME N/AN/ASeattle WA Hellstrom; Ingegerg N/AN/A Seattle WA Hellstrom; Karl Erik N/AN/A Seattle WA Bruce; Kim Folger N/AN/AWA Seattle Schreiber; George J.

US-CL-CURRENT: 424/130.1; 424/134.1, 424/155.1, 530/387.7, 530/388.8, 530/391.1

ABSTRACT:

The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant ER96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high legree of selectivity for carcinoma cells and possess the ability to mediate antibody dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations are cytotoxic when used in the unmodified form, at specified concentrations.

7 Claims, 75 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 74

								10030	I serves
F	Title Citation	r Front	Review	Classification	Date	Reference	Claims	KOOL	Image
7.0	Title Cash		-						

13. Document ID: US 5864028 A

File: USPT Entry 13 of 36

Jan 26, 1999

US-PAT-NO: 5864028

DOCUMENT-IDENTIFIER: US 5864028 A

TITLE: Degradation resistant mRNA derivatives linked to TNF-.alpha. ribozymes

DATE-ISSUED: January 26, 1999

INVENTOR-INFORMATION: COUNTRY ZIP CODE STATE CTTYNAME XON N/A N/AOslo Sioud; Mouldy

US-CL-CURRENT: 536/23.1; 435/6, 435/91.31, 536/24.1, 536/24.5

ABSTRACT:

This invention describes compounds active against TNF-.alpha. mRNA. It further describes RNA molecules capable of conferring stability to RNA in vivo through an endogenous ribozyme binding protein(s). Possible mRNA molecules to be stabilized include rikozymes, antisense molecules and mRNA encoding polyreptides useful for protein production. The ribozymes and antisense molecules described herein are useful in mammals and plants, particularly suited for viral diseases. Methods of production and methods of use are also described.

5 Claims, 79 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 51

14. Document ID: US 5849580 Λ

Entry 14 of 36

File: USPT

Dec 15, 1998

US-PAT-NO: 5849580

DOCUMENT IDENTIFIER: US 5849580 A

TITLE: Nucleic acid encoding a NF-.kappa.B activation regulatory protein. I.kappa.B.beta.

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY
Ghosh; Sankar Madison CT N/A N/A

US-CL-CURRENT: 435/325; 435/243, 435/320.1, 536/23.5

ABSTRACT:

The present invention provides a novel polypeptide, I.kappa.B-.beta., which binds to and affects NF-.kappa.B gene activation. Also provided is the nucleotide sequence encoding I.kappa.B-.beta. and methods of identifying compositions which affect I.kappa.B-.beta./NF.kappa.B complexes. Methods of treatment of disorders associated with NF-.kappa.E induced gene activation are also described herein.

9 Claims, 20 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 18

Full Title Offation Front Review Classification Date Reference Claims NMC Image

15. Document ID: US 5843723 A

Entry 15 of 36 File: USPT Dec 1, 1998

US-PAT-NO: 5843723

DOCUMENT-IDENTIFIER: US 5843723 A

TITLE: Alphavirus vector constructs

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dubensky, Jr.; Thomas W.	Rancho Sante Fe	CA	N/A	N/A
Polo: John M.	San Diego	CA	N/A	N/A
Ibanez; Carlos E.	San Diego	CA	N/A	N/A
Chang; Stephen M. W.	San Diego	CA	N/A	N/A
Jolly; Douglas J.	Leucadia	CA	N/A	N/A
Driver; David A.	San Diego	CA	N/A	N/A
Belli; Barbara A.	San Diego	CA	N/A	N/A
175 1 2 2 1				

US-CL-CURRENT: 435/69_3; 435/235_1, 435/320_1, 435/325

ABSTRACT:

The present invention provides compositions and method,, for utilizing recombinant alphavirus vectors.

47 Claims, 37 Drawing figures

4/ Claims, 3/ Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 30

				,			
Full Title Citation From	Review	Classification	Date	Reference	Claims	KNOTE	Image

16. Document ID: US 5840297 A

Entry 16 of 36

File: USPT

Nov 24, 1998

US-PAT-NO: 5840297

DOCUMENT-IDENTIFIER: US 5840297 A

TITLE: Vaccine comprising anti-idiotypic antibody to chlamydia GLXA and process

DATE-ISSUED: November 24, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
MacDonald; Alex Bruce	Amherst	MA	N/A	N/A
An; Ling-Ling	La Jolla	CA	N/A	N/A
Sutton-Stuart; Elizabeth	Amherst	MA	N/A	N/A
Whittum-Hudson; Judith A.	Elkton	MI)	N/A	N/A

US-CL-CURRENT: 424/131_1; 424/134_1, 424/150_1, 424/151_1, 424/263_1, 435/327, 435/340, 435/342, 530/387.2, 530/388.4, 530/388.6

ABSTRACT:

A genus specific chlamydia vaccine is provided which comprises an anti-idiotype antibody capable of producing in an animal an anti-anti-idiotypic antibody which recognizes a glycoplipid exoantigen (GLXA) of chlamydia. The vaccine is produced by producing an idiotypic antibody to GLXA which, in turn, is utilized t produce the anti-idiotypic antibody comprising the vaccine.

File: USPT

17 Claims, 17 Drawing figures Exemplary Claim Number: 5 Number of Drawing Sheets: 9

Full Title Citation Front Review Classification Date Reference Claims KMC	Image

17. Document ID: US 5821337 A

Entry 17 of 36

US-PAT-NO: 5821337 DOCUMENT-IDENTIFIER: US 5821337 A

TITLE: Immunoglobulin variants

DATE-ISSUED: October 13, 1998

INVENTOR - INFORMATION:

COUNTRY ZIP CODE CITY STATE NAME N/AN/A CA San Francisco Carter; Paul J. N/A N/ACASan Francisco Presta; Leonard G.

US-CL-CURRENT: 530/387.3; 424/133.1, 530/350, 530/388.2

ABSTRACT:

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

15 Claims, 12 Drawing figures Exemplary Claim Number: 3 Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC	Image

18. Document ID: US 5814482 A

Entry 18 of 36

File: USPT

Sep 29, 1998

Oct 13, 1998

US-PAT-NC: 5814482

DOCUMENT-IDENTIFIER: US

5 14482 A

TITLE: Eukaryotic layered vector initiation systems

DATE-ISSUED: September 29, 1998

INVENTOR-INFORMATION:

COUNTRY ZIP CODE STATE CITY NAME N/A92067 Rancho Sante Fe CA Dubensky, Jr.; Thomas W. N/A 9::109 CA San Diego Polo; John M. N/A9210214 CA Leucadia Jolly; Douglas J. N/A 92117 CA San Diego Driver; David A.

US-CL-CURRENT: 435/69_3; 435/320_1, 536/23_1, 536/24_1

ABSTRACT:

The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eugaryotic layered vector initiation systems.

25 Claims, 37 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 30

Claims 12000	
Full Title Ottation Front Review Classification Date Reference Claims KMMC	HHERE

19. Document ID: US 5789245 A

Entry 19 of 36

File: USPT

Aug 4, 1998

US-PAT-NO: 5789245

DOCUMENT-IDENTIFIER: US 5789245 A

TITLE: Alphavirus structural protein expression cassettes

DATE-ISSUED: August 4, 1998

INVENTOR - INFORMATION:

ZIF CODE COUNTRY STATE CITY NAME N/A N/ACARancho Sante Fe Dubensky, Jr.; Thomas W. N/A N/ACA San Diego Polo; John M. N/A CA N/ASan Diego Ibanez; Carlos E. N/AN/A CASan Diego Chang; Stephen M. W. N/AN/ACA Leucadia Jolly; Douglas J. CA N/Λ N/ASan Diego Driver; David A.

US-CL-CURRENT: 435/320.1; 435/325, 435/69.1, 536/23.72

ABSTRACT:

The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

29 Claims, 35 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 30

									-	
Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KAMC	lmage
1.911	1111-	O Marie !								

20. Document ID: US 5760102 A

Entry 20 of 36

File: USPT

Jun 2, 1998

DOCUMENT-IDENTIFIER: US 50102.

TITLE: Uses of denture adhesive containing aloe extract

DATE ISSUED: June 1, 1993

INVENTOR INFORMATION:

NAME
Hall; John E.
Grand Frairie
TX
N/A
Yates; Kenneth M.
Grand Frairie
TX
N/A
N/A

US-CL-CURRENT: 523/120; 433/180, 524/27, 524/78, 536/123.1, 536/4.1

ABSTRACT:

A method of adhering a denture, having a biocontact surface, to a gum or a roof of a mouth, containing the steps of: (1) Treating the biocontact surface of the denture with a denture adhesive composition containing a chemical substance derived from an aloe leaf to obtain a treated denture; and (2) placing the treated denture in close proximity to a gum or the roof of the mouth thereby engaging the treated denture with the gum or the roof of the mouth. A method of preparing a denture adhesive composition containing a chemical substance derived from an aloe leaf.

33 Claims, 22 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 11

			-			_		The state of the s		
Foll	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMMC	Image
011	11112	O RESIDENT								

Generate Collection

Term	Documents
MEDIUM.USPT.	434584
MEDIUMS USPT.	12523
MEDIA.USPT.	156490
MEDIAS USPT.	583
MEDIA.USPT.	156490
MEDIUM.USPT.	434584
MEDIUMS USPT.	12523
MEDIAS USPT.	583
(5 AND (MEDIUM OR MEDIA)) USPT.	36

Display 20 Documents including document number 21

Display Format: REV Change Format

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers

Help Logout

WEST

Help Logout

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers

Generate Collection

Search Results - Record(s) 21 through 36 of 36 returned.

21. Document ID: US 5744139 A

Entry 21 of 36

File: USPT

Apr 28, 1998

US-PAT-NO: 5744139

DOCUMENT-IDENTIFIER: US 5744139 A

TITLE: Insulin-like growth factor I (IGF-1) induced improvement of depressed T4/T8

ratios

DATE-ISSUED: April 28, 1998

INVENTOR - INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Kudsk; Kenneth A.

Memphis

'TN

N/A

N/A

US-CL-CURRENT: 424/198.1; 424/185.1, 514/12, 514/2, 514/21, 530/300, 530/350, 530/399, 530/868

ABSTRACT:

A method for increasing the T4/T8 ratio in a human with a depressed T4/T8 ratio comprising administering insulin-like growth factor I (IGF-1) is disclosed. 12 Claims, 63 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 27

Full Title Citation Front Review Classification Date Reference Claims KWIC Image

22. Document ID: US 5741648 A

Entry 22 of 36

File: USPT

Apr 21, 1998

US-PAT-NO: 5741648 DOCUMENT IDENTIFIER: US 11648 A

TITLE: Cell analysis method using quantitative fluorescence image analysis

DATE-ISSUED: April 21, 1998

INVENTOR - INFORMATION:

ZIP CODE COUNTRY STATE CITYNAME N/A N/AOklahoma City OKHemstreet, III; George P. N/AN/A Oklahoma City OF. Hurst; Robert E. N/A N/AOklahoma City CKBonner; Rebecca B. N/AN/A $\mathbb{C}\mathbb{K}$ Edmond Rao; Jian Yu

US-CL-CURRENT: 435/6; 435/7.21, 435/7.23, 436/63, 436/64, 436/813

ABSTRACT:

A system for evaluating one or more biochemical markers for evaluating individual cancer risk, cancer diagnosis and for monitoring therapeutic effectiveness and cancer recurrence, particularly of bladder cancer. The system uses automated quantitative fluorescence image analysis of a cell sample collected from a body organ. Cells are treated with a fixative solution which inhibits crystal formation. Cell images are selected and stored as grey level images for further analysis. Cell images may be corrected for autofluorescence using a novel autofluorescence correction method. A neural net computer may be used to distinguish true-positive images from false-positive images to improve accuracy of cancer risk assessment. Cells having images positive for a marker amy be compared to threshold quantities related to predetermined cancer risk.

39 Claims, 31 Drawing figures

39 Claims, 31 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 24

Full	Title	Citation		Classification					
######################################	***************************************		 5500. \$11.11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		erenentro (m. control	×	 reference and		

23. Document ID: US 5733721 A

Entry 23 of 36

File: USPT

US-PAT-NO: 5723721 DOCUMENT IDENTIFIER: US

TITLE: Cell analysis method using quantitative fluorescence image analysis

DATE-ISSUED: March 31, 1998

INVENTOR-INFORMATION:

ZIP CODE COUNTRY STATE CITY NAME N/AN/AOF. Oklahoma City Hemstreat, III; George P. N/A N/AOklahoma City OK Hurst; Robert E. N/A OKN/AOklahoma City Bonner; Rebecca B. N/AΟK N/AEdmond Rao; Jian Yu

US-CL-CURRENT: 435/6; 382/133, 435/7.23, 435/968, 435/973, 436/800, 436/805

ABSTRACT:

A system for evaluating one or more biochemical markers for evaluating individual cancer risk, cancer diagnosis and for monitoring therapeutic effectiveness and cancer recurrence, particularly of bladder cancer. The system uses automated quantitative fluorescence image analysis of a cell sample collected from a body organ. Cells are treated with a fixative solution which inhibits crystal formation. Cell images are selected and stored as grey level images for further analysis. Cell images may be corrected for autofluorescence using a novel autofluorescence correction method. A neural net computer may be used to distinguish true-positive images from faise-positive images to improve accuracy of cancer risk assessment. Cells having images positive for a marker amy be compared to threshold quantities related to predetermined cancer risk.

143 Claims, 31 Drawing figures Exemplary Claim Number: 143 Number of Drawing Sheets: 24

								1	LANGO	
Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KRONG	lwage :
- 0"	11111	2 10 11 11		سسم						

24. Document ID: US 5716793 A

Entry 24 of 36

File: USPT

Feb 10, 1998

US-PAT-NO: 5716793

DOCUMENT-IDENTIFIER: US 5716793 A

TITLE: Method for diagnosing a patient for chlamydia

DATE-ISSUED: February 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
MacDonald; Alex Bruce	Amherst	MA	N/A	N/A
Stuart; Elizabeth S.	Amherst	MA	N/A	N/A
An; Ling Ling	La Jolla	CA	N/A	N/A
Whipkey; Myron D.	Portland	ME	N/A	N/A

US-CL-CURRENT: 435/7.36; 424/150.1, 424/163.1, 424/263.1, 435/7.32, 435/7.9, 435/7.92, 435/7.94, 435/7.95, 435/965, 436/518, 436/536, 436/548, 436/811, 530/388.4, 530/389.5

ABSTRACT:

A method of detecting chlamydia in a extracellular sample is provided which comprises contacting the sample with an idiotypic antibody to GLXA to form an immunocomplex and detecting the immunocomplex.

10 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full Titl	e Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image

Entry 25 of 35 Fife: USPT

US PAT NO: 5638657

DOCUMENT-IDENTIFIER: US 5688657 A

TITLE: Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor

DATE-ISSUED: November 18, 1997

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY
Tsang; Kwong Y. Bethesda MD N/A N/A
Arlen; Myron Great Neck NY N/A N/A

US-CL-CURRENT: 435/7.23; 435/325, 435/328, 435/329, 435/330, 435/332, 435/344, 435/40.51, 435/40.52, 435/7.1, 435/7.2, 530/387.1, 530/387.3, 530/387.5, 530/387.7, 530/388.1, 530/388.8, 530/391.1, 530/391.3, 530/391.7

ABSTRACT:

Monoclonal antibodies, in particular 33.28 and 31.1, and chimeric antibodies, in particular mouse/human chimeric Chi #1 specific for glycoprotein antigens of colon carcinoma-associated antigens which are immunogenic in humans, are disclosed. Such antibodies, and fragments and derivatives thereof, are useful in immunotiagnosis and immunotherapy of human colon, breast, and ovarian cancer, and for purification of antigens which can serve as immunotherapeutic agents. Methods of detecting the colon carcinoma-associated antigen in a sample, and methods for treating subjects having colon, breast, and ovarian carcinomas are disclosed.

50 Claims, 4 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 4

Full Title Citation Front Review Classification Date Reference Claims KMC Image

26. Document ID: US 5665540 A

Entry 26 of 36

File: USPT

Sep 9, 1997

Mry 18, 1997

US-PAT-NO: 5665540

DOCUMENT-IDENTIFIER: US 5665540 A

TITLE: Multicolor in situ hybridization methods for genetic testing

DATE-ISSUED: September 9, 1997

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUPTRY Lebo; Roger V. San Francisco CA N/A N/A

US-CL-CURRENT: 435/6; 436/811

ABSTRACT:

This invention relates to novel methods of optimally analyzing commonly obtained prenatal cell samples by in situ hybridization. In addition, this method diagnoses gene deletion and gene multiplication using multicolor in situ hybridization. A method is also provided to use multicolor in situ hybridization to identify chromosomal haplotypes co-segregating with disease-related genetic alterations and with normal genes. This haplotype in situ protocol simplifies haplotype segregation analysis in pedigrees.

21 Claims, 9 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 2

	**************************************								13615	
Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KOMU	image :

DOCUMENT IDENTIFIEF: US 5656271 A

TITLE: Oral vaccine comprising anti-idictypic antibody to chlamydia glycolipid exoantigen and process

DATE ISSUED: August 12, 1997

INVENTOR INFORMATION:

COUNTRY ZIP CODE STATE CITY NAME N/AN/A MA Hatfield MacDonald; Alex Bruce N/AN/A MD Elkton Whittum-Hudson; Judith A. N/A N/ABaltimore MSaltzman; William Mark

US-CL-CURRENT: 424/131.1; 424/151.1, 424/263.1, 424/486, 424/492, 424/493, 424/497, 530/387.2, 530/388.4, 530/389.5

ABSTRACT:

A genus specific chlamydia oral or injectable vaccine is provided which comprises an anti-idiotype antibody capable of producing in an animal an anti-idiotypic antibody or Fab fragment thereof enclosed in microspheres formed of a pharmacologically acceptable polymer is capable of producing in an animal an anti-anti-idiotypic immune response (serum antibody, secretary antibody or T-cell responsee) which recognizes a glycolipid exoantigen (GLXA) of chlamydia. The oral or injectable vaccine is produced from an idiotypic antibody to GLXA which, in turn, is utilized to produce the anti-idiotypic antibody.

15 Claims, 19 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 10

	F-1									
Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Image

28. Document ID: US 5654148 A

Entry 28 of 36

File: USPT

Aug 5, 1997

US-PAT-NO: 5654148

DOCUMENT-IDENTIFIER: US 5654148 A

TITLE: Multicolor in situ hybridization methods for genetic testing

DATE-ISSUED: August 5, 1997

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Lebo; Roger V.

San Francisco

CA

N/A

N/A

US-CL-CURRENT: 435/6; 435/5

ABSTRACT:

This invention relates to novel methods of optimally analyzing commonly obtained prenatal cell samples by in situ hybridization. In addition, this method diagnoses gene deletion and gene multiplication using multicolor in situ hybridization. A method is also provided to use multicolor in situ hybridization to identify chromosomal haplotypes co-segregating with disease-related genetic alterations and with normal genes. This haplotype in situ protocol simplifies haplotype segregation analysis in pedigrees.

analysis in pedigrees.
6 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image

29. Document ID: US 5597898 A

US-PAT-ND: 5597898

DOCUMENT IDENTIFIER: US



TITLE: NF .kappa.B activation regulatory protein, I.kappa.B .beta.

DATE-ISSUED: January 28, 1997

INVENTOR INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Ghosh; Sankar

Madison

CT

N/A

N/A

US-CL-CURRENT: 530/350

ABSTRACT:

The present invention provides a novel polypeptide, I.kappa.B-.beta., which binds to and affects NF-.kappa.B gene activation. Also provided is the nucleotide sequence encoding I.kappa.B-.beta. and methods of identifying compositions which affect I.kappa.B-.beta..backslash.NF-.kappa.B complexes. Methods of treatment of disorders associated with NF-.kappa.B induced gene activation are also described herein.

1 Claims, 20 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 13

Full, Title Citation Front Review Classification Date Reference Claims KMC Image.

30. Document ID: US 5447842 A

Entry 30 of 36

File: USPT

Sep 5, 1995

US-PAT-NO: 5447842

DOCUMENT-IDENTIFIER: US 5447842 A

TITLE: Fetal cell recovery method

DATE-ISSUED: September 5, 1995

INVENTOR - INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Simons; Malcolm J.

Glerluce

N/A

N/A

XUA

US-CL-CURRENT: 435/6; 435/2, 435/29, 435/30, 435/378, 435/7.21, 435/7.24, 435/7.25

ABSTRACT:

The present invention provides a method for selectively recovering fetal cells from a maternal blood sample. The method is performed on a blood sample from a pregnant woman having different first and second cell surface antigens expressed by a first allele of a polymorphic genetic locus and a second allele of a polymorphic genetic locus. The method separates maternal and fetal cells based on differential reactivities of the cells to antibodies specific for polymorphic cell surface antigens, particularly the HLA antigens. In particular, the fetal and maternal cells are separated based on the non-reactivity of the fetal cells to an antibody specific for a cell surface antigen encoded by a non transmitted maternal allele. The method can be performed using solid phase-affixed antibody and recovering non-bound cells or using fluorescent labeled antibody and recovering unlabeled cells by fluorescence-activated cell sorting. In a preferred embodiment, the cells are also contacted with a second antibody specific for the second cell surface antigen. Fetal cells are separated based on their reaction with, at most, one of the antibodies. Exemplary Claim Number: 1

Full Title Citation Front Review Classification Date Reference Claims KWIC Image

31. Document ID: US 5292636 A

Entry 31 of 36

File: USPT

Mar 3, 1994

DOCUMENT IDENTIFIEF: US \$2636 A

TITLE: Therapeutic and diagnostic methods using soluble T cell surface molecules

DATE-ISSUED: March 8, 1994

INVENTOR INFORMATION:

STATE ZIP CODE COUNTRY CITY NAME N/AMA N/ALexington Kung; Patrick C. N/A MΑ N/ASudbury Ip; Stephen H. N/AN/A. MΑ Wayland Brown; Michael C. N/A PAN/AElkins Park MacKeen; Linda A.

US-CL-CURRENT: 435/5; 435/34, 435/7_23, 435/7_24, 435/7_9, 435/7_94, 435/974, 435/975, 436/506, 436/518, 436/536, 436/548, 436/811, 436/813

ABSTRACT:

The present invention is directed to the measurement of soluble T cell growth factor receptors, soluble T cell differentiation antigens, or related soluble molecules or fragments thereof, and the use of such measurements in the diagnosis, staging, and therapy of diseases and disorders. Specific embodiments involve the diagnosis and monitoring of therapy using absolute values of such soluble molecules. Further embodiments involve detecting a change in the levels of such soluble molecules, in the diagnosis and therapy of diseases and disorders. In specific embodiments, measurements of interleukin-2 receptor levels can be made to detect lung cancer, or to stage squamous cell lung carcinoma. In other embodiments, detection of increases in both soluble IL2R and creatinine in the body fluid of a transplant patient can be used to differentially diagnose renal allograft rejection from infection. The invention is also directed to methods for measurement of soluble CD4 antigens, which measurements can be used, in a specific embodiment, to diagnose a state of immune activation, to diagnose rheumatoid arthritis, to monitor therapeutic efficacy (e.g. of AIDS treatments), or to stage adult T cell leukemia in a patient. In another aspect, the invention relates to the detection, staging, and monitoring of therapy of diseases and disorders by measuring a plurality of soluble T cell markers.

37 Claims, 35 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 28

1	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	simage
	111111111111111111111111111111111111111	2 1000 11-11								

32. Document ID: US 5242820 A

Entry 32 of 36

File: USPT

Sep 7, 1993

DOCUMENT LIDENTIFIER: US 42920 A

TITLE: Pathogenic mycoplasma

DATE-ISSUED: September 7, 1901

INVENTOR INFORMATION:

NAME

CTTY

STATE

ZIP CODE

COUNTRY

Lo; Shyh-Ching

Potomac

MD

N/A

N/A

US-CL-CURRENT: 435/252.1; 435/5, 435/872

ABSTRACT:

The invention relates to a novel pathogenic mycoplasma isolated from patients with Acquired Immune Deficiency Syndrome (AIDS) and its use in detecting antibodies in sera of AIDS patients, patients with AIDS-related complex (ARC) or patients dying of diseases and symptoms resembling AIDS diseases. The invention further relates to specific DNA sequences, antibodies against the pathogenic mycoplasma, and their use in detecting DNA or antigens of the pathogenic mycoplasma or other genetically and serologically closely related mycoplasmas in infected tissue of patients with AIDS or ARC or patients dying of symptoms resembling AIDS diseases. The invention still further relates to a variety of different forms of vaccine against mycoplasma infection in humans and/or animals.

Full Title Citation Front Review Classification Date Reference Claims KMC Image

33. Document ID US 5225542 A

Entry 33 of 36

File: USPT

Jul 6, 1993

US-PAT-NO: 5225542

DOCUMENT-IDENTIFIER: US 5225542 A

TITLE: Specific Carbohydrate-binding proteins (lectins) of mammalian tumor cells

DATE-ISSUED. July 6, 1993

INVENTOR - INFORMATION:

NAME Cramer; Friedrich Gabius; Hans-Joachim CITY Goettingen

Goettingen

STATE N/A

N/A

ZIP CODE N/A

N/A

DEX DEX

COUNTRY

US-CL-CURRENT, 530/396

ABSTRACT:

Carbohydrate-binding proteins (lectins) of mammalian tumor cells and processes for their preparation. These lectins, the corresponding carbohydrates and the corresponding monoclonal antibodies are suitable for rapid, reliable and precise differential diagnosis of tumors and for the product of pharmaceutical compositions for the treatment of tumors.

29 Claims, 2 Drawing figures
Exemplary Claim Number: 1

Full Title Citation Front Review Classification Date Reference Claims KWIC Image

34. Document ID: US 4917890 A

Number of Drawing Sheets: 2

Entry 34 of 36

File: USPT

Apr 17, 1990

DUCUMENT IDENTIFIER: US 17890 A

TITLE: Processes for preparation of alce products, products produced thereby and compositions thereof

DATE-ISSUED: April 17, 1990

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

McAnalley; Fill H. Grand Prairie TX N/A N/A

US-CL-CURRENT: 424/195.1; 424/DIG.13, 426/658, 514/25, 514/458

ABSTRACT:

Processes for producing aloe extracts including the separation of the leaves of the aloe plant into distinct portions. In particular, a first process is described for producing an aloe extract which is substantially free of anthraquinone-rich yellow sap and a second process is described for extracting the active chemical substance in the aloe plant.

The active chemical substance in the aloe plant is extracted from aloe leaves and its characteristic properties are described.

63 Claims, 28 Drawing figures Examplary Claim Number: 1 Number of Drawing Sheets: 28

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC	image

35. Document ID: US 4775620 A

Entry 35 of 36 File: USPT

Oct 4, 1988

US-PAT-NO: 4775620

DOCUMENT'-IDENTIFIER: US 4775620 A

TITLE: Cytokeratin tumor markers and assays for their detection

DATE-ISSUED: October 4, 1988

INVENTOR-INFORMATION:

ZIP CODE COUNTRY STATE NAME CITY N/A N/A Davis CACardiff; Robert D. CA N/AN/ARossitto: Paul V. Sacramento N/AMDN/AAndrews Air Force Base Brabon: Alan C.

US-CL-CURRENT: 435/7.23; 435/29, 435/70.21, 431/810, ±35/975, 436/519, 436/548, 436/813, 530/357, 530/388.2, 530/388.85, 530/828

AESTRACT:

Methods and compositions are provided for identifying patients suffering from neoplastic diseases such as breast cancer. It has been found that neoplastic epithelial cells, including neoplastic mammary epithelial cells, release a particular N-terminal blocked, soluble cytokeratin into circulation. The presence of this cytokeratin is diagnostic of neoplastic disease.

34 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full Title Citation Front Review Classification Date Reference Claims KWIC Image

36. Document ID: US 4735935 A

Entry 36 of 36

File: USPT

Apr 5, 1988

DOCUMENT IDENTIFIER: US

TITLE: Process for preparation of also products products, produced thereby and

compositions thereof

DATE ISSUED: April 5, 1988

INVENTOR INFORMATION:

NAME

CITY

STATE

ZIP CODE

CCUNTRY

McAnalley; Bill H.

Grand Prairie

-n.X

N/A

N/A

US-CL-CURRENT: 514/53; 124/DIG.13, 514/54, 514/847, 536/123, 536/53

ABSTRACT:

Process for producing also extracts including the separation of the leaves of the also plant into distinct portions. In particular, a first process is described for producing an aloe extract which is substantially free of anthraquinene-rich yellow sap and a second process is described for extracting the active chemical substance in the aloe plant.

The active chemical substance in the aloe plant is extracted from aloe leaves and its characteristic properties are described.

5 Claims, 32 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 28

Citation Front Review Classification Date Reference Claims

Generate Collection

Term				Documents
MEDIUM.USPT.			/4.4./ 55	434584
MEDIUMS.USPT			in type TE A, E	12523
MEDIA.USPT.			1 11 m	156490
MEDIAS.USPT.				583
MEDIA.USPT.			. S Miller Mar 63 od	156490
MEDIUM USPT	.1 931	:	2 00 10 1 March 1 100	434584
MEDIUMS.USPT.		, i.e.		12523
MEDIAS.USPT.	0			583
(5 AND (MEDIUM OR MEDIA)) USPT			y	36
(6 11.12 (22				A second of the

Display 20 Documents

including document number 265

Display Format: FEV

Change Format

Main Menu	Search Form	Posting Counts	Show S Numbers	Edit S Numbers
	-			

Help

Logout